Diffuse Large B-Cell Lymphoma Associated with Wiskott-Aldrich Syndrome: A Case Report
Archives of Advances in Biosciences,
Vol. 16 No. 1 (2025),
2 March 2025
,
Page 1-3
https://doi.org/10.22037/aab.v16i1.47683
Abstract
Context: Wiskott-Aldrich syndrome (WAS) is an X-linked primary immunodeficiency characterized by microthrombocytopenia, eczema, recurrent infections, and a significant predisposition to autoimmune diseases and malignancies, particularly B-cell lymphomas.
Case presentation: We report the case of a 14-year-old male with a confirmed diagnosis of WAS since infancy, who later developed Crohn’s disease. He presented with vegetative lesions in the rectum and transverse colon, which were diagnosed as diffuse large B-cell lymphoma (DLBCL) based on immunohistochemistry and positive EBV-encoded small RNAs (EBER). The patient received 12 cycles of chemotherapy, including Rituximab and Etoposide, along with intravenous immunoglobulin (IVIG) support.
Conclusion: This is a rare case of EBV-associated DLBCL in a WAS patient from Iran. The case highlights the importance of early and routine malignancy screening in WAS patients, even in the absence of significant symptoms. Molecular and immunophenotypic assessments, including PCR and immunohistochemistry, are essential for accurate diagnosis and management.
- DLBCL
- Wiskotte-Aldrich
How to Cite
References
Candotti F. Clinical manifestations and pathophysiological mechanisms of the Wiskott-Aldrich syndrome. Journal of clinical immunology. 2018 Jan;38(1):13-27. [PMID]
Ochs HD, Filipovich AH, Veys P, Cowan MJ, Kapoor N. Wiskott-Aldrich syndrome: diagnosis, clinical and laboratory manifestations, and treatment. Biology of Blood and Marrow Transplantation. 2009 Jan 1;15(1):84-90. [PMID]
Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell. 1994 Aug 26;78(4):635-44. [PMID]
Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. The Journal of pediatrics. 1994 Dec 1;125(6):876-85.[PMID]
Bosticardo M, Marangoni F, Aiuti A, Villa A, Grazia Roncarolo M. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood, The Journal of the American Society of Hematology. 2009 Jun 18;113(25):6288-95. [PMID]
Stewart DM, Treiber-Held S, Kurman CC, Facchetti F, Notarangelo LD, Nelson DL. Studies of the expression of the Wiskott-Aldrich syndrome protein. The Journal of clinical investigation. 1996 Jun 1;97(11):2627-34.[PMID]
Symons M, Derry JM, Karlak B, Jiang S, Lemahieu V, McCormick F, Francke U, Abo A. Wiskott–Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell. 1996 Mar 8;84(5):723-34. [PMID]
Ochs HD. The Wiskott-Aldrich syndrome. Clinical reviews in allergy & immunology. 2001 Feb;20(1):61-86. [PMID]
Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK. Immunodeficiency-associated lymphomas. Blood reviews. 2008 Sep 1;22(5):261-81. [PMID]
Du S, Scuderi R, Malicki DM, Willert J, Bastian J, Weidner N. Hodgkin's and non-Hodgkin's lymphomas occurring in two brothers with Wiskott-Aldrich syndrome and review of the literature. Pediatric and Developmental Pathology. 2011 Jan;14(1):64-70. [PMID]
Bu M. Cancer in children with primary or secondary immunodeficiencies. J Pediatr. 1995;126:1-0. [PMID]
- Abstract Viewed: 109 times
- PDF Downloaded: 74 times